红细胞生成素治疗血液透析贫血患者给药途径的临床研究

Comparative Study on Erythropoietin with Various Administration Routes in Hemodialysis Patients with Anemia

人基因重组红细胞生成素 (r Hu Epo)治疗肾性贫血疗效显著 ,在临床有不同的给药途径。为探讨r Hu Epo治疗血液透析贫血患者的给药途径 ,随机将 35例分为皮下注射组和静脉注射组 ,结果显示 ,所有患者贫血均明显缓解 ,两组患者的 Hb、RBC、Hct均明显上升 ,两组比较无显著性差异 (P>0 .0 5 ) ,而皮下组维持剂量低于静脉组 ,节约药量且操作方便 ,可减少不良反应。提示 r Hu Epo皮下注射效果良好 ,且具有经济实用的优点。

In order to investigate the administrating route of erythropoietin to treat hemodialysis associated anemia patients, 35 cases of hemodialysis were randomly divided into subcutaneous injection group and intravenous injection group. The results showed all patients obtained an obvious remission. The Hb, RBC and Hct were all significantly increased in both groups. No significant difference was found between the two groups ( P >0 05). The maintenance dose in the subcutaneous injection group was obviously lower than in the intravenous injection group. It was concluded that erythropoietin subcutaneously given could obtain better effects and may be preferable to optimize response at the aspect of technique, cost and curative effect.